The technology we participate to develop, called "Zinc-Finger Artificial Transcription Factors (ZF-ATFs)", allows to design, realize and select artificial genes coding for proteins capable of recognizing and binding "potentially" any DNA sequence. We used ZF-ATF technology to reprogram the expression of "beneficial" genes capable of efficiently counteracting the negative effect of mutated genes related to rare diseases.
Technologies
In this section it is possible to view, also through targeted research, the technologies inserted in the PROMO-TT Database. For further information on the technologies and to contact the CNR Research Teams who developed them, it is necessary to contact the Project Manager (see the references at the bottom of each record card).
Displaying results 1 - 9 of 9
CNR-ISTEC develops geopolymer composites for thermostructural applications, such as: self-supporting cavities; thermal and acoustic insulation; thermal and fire barriers; high temperature coatings and damping; molds and cores for foundry; foams and refractory linings. Geopolymers are chemically bonded materials at T <300 ° C. Being inorganic polymers without water in the structure, they tolerate high temperatures: they are incombustible, do not emit gas or fumes and do not explode.
WembraneX is an Italian start-up born with the ambition to make a significant contribution to UN Sustainable Goal 6 - Ensure Access to Clean Water and Sanitation for all by 2030.
An innovative approach for the treatment of diabetic and venous ulcers, characterized by a difficult healing process and therefore at potential risk of infection and therefore of hospitalization and amputation of the limb, is represented by the local administration of "bioactive" factors through the use of synthetic and/or biological matrices that allow a gradual and controlled release in order to obtain a better and faster healing.
Recently, nanoparticles and nanovesicles have been investigated as potential approaches for the treatment of neurodegenerative diseases. In particular, in the Biotech sector an increasingly deeper penetration of new treatment models and biological drugs based on cellular, subcellular and vesicle therapies is expected. The patent is based on the production of Myelin-based nanoVesicles (MyVes) produced by microfluidics, starting from myelin extracted from brain tissue. These vesicles find two major fields of applications as potential drugs or as supplements/nutraceuticals.
The invention relates to the water purification sector; it refers to a phytodepuration module and to a plant including this module. The objective is decontamination and recovery of drinking water from contaminated springs and wells, thermal, rainwater, wastewater and industrial wastewater. Phytodepuration tanks are known which use ferns to decontaminate water, but have the limits of requiring large surfaces and / or long treatment times.
We present a technology for the multiscale isolation (analytical-laboratory-production) of Extracellular Vesicles (VE), which overcomes the limitations of the currently available methods. As opposed to traditional "affinity-based" systems that exploit antibodies, our technology represents a radical paradigm shift in the development of affinity probes for vesicles, i.e.
Geopolymers belong to the class of chemically bonded ceramics: they are synthesized at low temperatures and are eco-friendly, as besides the low consolidation temperature required by the process they can be produced from secondary raw materials and industrial waste of various kinds, thus reducing the energy demand and the environmental impact of the entire production cycle. Materials such as fly ash, steel mill slag, biomass ash, sludge and silt, extractive residues, mineral and ceramic powders, organic or inorganic waste fibers, plastics, etc.
Safe, efficient and specific nano-delivery systems are increasingly needed for precision and regenerative medicine and targeted therapies (e.g. anticancer and antimicrobial therapies), as well as for the cosmetic and nutraceutical sectors’ applications. Despite the appreciable success of synthetic nanovectors, like for example liposomes, their clinical and market application is hampered by some limitations: • large scale production, • low cost production • intrinsic toxicity • limited cellular uptake • limited consumer acceptance.